Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Shandong Xinhua Pharmaceutical Co's Debt-to-Equity or its related term are showing as below:
SHNXY'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.27 Med: 0.37 Max: 0.75
Current: 0.27
During the past 13 years, the highest Debt-to-Equity Ratio of Shandong Xinhua Pharmaceutical Co was 0.75. The lowest was 0.27. And the median was 0.37.
SHNXY's Debt-to-Equity is ranked better than 51.3% of 809
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs SHNXY: 0.27
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Shandong Xinhua Pharmaceutical Co Debt-to-Equity Related Terms
Shandong Xinhua Pharmaceutical Co Debt-to-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Xinhua Pharmaceutical Co Debt-to-Equity Chart
For the Drug Manufacturers - Specialty & Generic subindustry, Shandong Xinhua Pharmaceutical Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shandong Xinhua Pharmaceutical Co Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Shandong Xinhua Pharmaceutical Co's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Shandong Xinhua Pharmaceutical Co's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shandong Xinhua Pharmaceutical Co (SHNXY) has a Debt-to-Equity of 0.27 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Shandong Xinhua Pharmaceutical Co and its competitors. This is 27% below median its historical median of 0.37. Over the past decade, Shandong Xinhua Pharmaceutical Co's Debt-to-Equity has ranged from 0.27 to 0.75. According to the industry distribution chart, Shandong Xinhua Pharmaceutical Co ranks #394 out of 809 companies in the Drug Manufacturers industry, placing it in the top 48.7%.
Is Shandong Xinhua Pharmaceutical Co's Debt-to-Equity too high?
Shandong Xinhua Pharmaceutical Co's current Debt-to-Equity of 0.27 is 27% below median its 10-year median of 0.37. Over the past 10 years, this metric has ranged from a low of 0.27 to a high of 0.75. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Shandong Xinhua Pharmaceutical Co's value of 0.27 is 3.6% below this industry median. Based on the distribution chart, Shandong Xinhua Pharmaceutical Co ranks #394 out of 809 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Shandong Xinhua Pharmaceutical Co has a GF Score™ of 88/100, reflecting its overall financial health beyond just this single metric.
How does Shandong Xinhua Pharmaceutical Co's Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Shandong Xinhua Pharmaceutical Co ranks #394 out of 809 companies for Debt-to-Equity. This puts Shandong Xinhua Pharmaceutical Co in the upper half of its industry. The industry median Debt-to-Equity is 0.28. Shandong Xinhua Pharmaceutical Co's value of 0.27 is 3.6% below this benchmark. Historically, Shandong Xinhua Pharmaceutical Co's own Debt-to-Equity has ranged from 0.27 to 0.75 over the past decade. While the company's 10-year median is 0.37 vs. the industry median of 0.28, Shandong Xinhua Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 809 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Shandong Xinhua Pharmaceutical Co's current Debt-to-Equity of 0.27 is 3.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Shandong Xinhua Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shandong Xinhua Pharmaceutical Co's current Debt-to-Equity is 0.27, which is 27% below median its own 10-year median of 0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shandong Xinhua Pharmaceutical Co stock overvalued right now?
Shandong Xinhua Pharmaceutical Co (SHNXY) has a current Debt-to-Equity of 0.27. The stock's GF Value™ is $21.95, compared to a current price of $18.19 — trading 17.1% below its estimated fair value. The current Debt-to-Equity is 0.27, which is 27% below median its 10-year median of 0.37 and 3.6% below the Drug Manufacturers industry median of 0.28. Shandong Xinhua Pharmaceutical Co's overall GF Score™ is 88/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Shandong Xinhua Pharmaceutical Co (SHNXY), the current Debt-to-Equity is 0.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shandong Xinhua Pharmaceutical Co (SHNXY) Overvalued in 2026?
Based on GuruFocus' analysis, Shandong Xinhua Pharmaceutical Co stock appears to be undervalued.
The current stock price of $18.19 is trading 17.1% below its estimated GF Value™ of $21.95.
Key valuation signals for SHNXY:
Debt-to-Equity: 0.27 (27% below median its 10-year median of 0.37)
GF Value™: $21.95 vs. price of $18.19 (17.1% below fair value)
Industry Position: 3.6% below the Drug Manufacturers median (#394 of 809)
No single metric tells the full story. See the SHNXY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shandong Xinhua Pharmaceutical Co Ltd is a pharmaceutical products manufacturer based in China. It operates various segments namely Chemical raw materials, Preparations, Pharmaceutical intermediates and other products. The company is mainly engaged in the business of development, manufacture and sale of bulk pharmaceuticals, preparations and chemical products.
88GF Score
Get the complete analysis for SHNXY
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHNXY has been successfully added to your 
